RT Journal Article
SR Electronic
T1 SARS-CoV-2 seroprevalence among healthcare workers in general hospitals and clinics in Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.23.21249922
DO 10.1101/2021.01.23.21249922
A1 Yoshihara, Tatsuya
A1 Ito, Kazuya
A1 Zaitsu, Masayoshi
A1 Chung, Eunhee
A1 Aoyagi, Izumi
A1 Kaji, Yoshikazu
A1 Tsuru, Tomomi
A1 Yonemura, Takuma
A1 Yamaguchi, Koji
A1 Nakayama, Shinichi
A1 Tanaka, Yosuke
A1 Yurino, Nobuo
A1 Koyanagi, Hideki
A1 Matsuki, Shunji
A1 Urae, Ryuji
A1 Irie, Shin
YR 2021
UL http://medrxiv.org/content/early/2021/01/25/2021.01.23.21249922.abstract
AB Coronavirus disease 2019 (COVID-19) has become a serious public health problem worldwide. However, little is known about the prevalence of COVID-19 among healthcare workers in Japan. We aimed to examine the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies among 2,160 healthcare workers in general hospitals and clinics in Japan. The prevalence of SARS-CoV-2 immunoglobulin G was 1.2% in August and October 2020, which is relatively higher than that in the general population in Japan. Because of the higher risk of COVID-19 infection, healthcare workers should be the top priority for further social support and vaccination against SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialUMIN000041262Funding StatementThis study did not receive external funding. The immunochromatographic assay kits used in this study were provided by SoftBank Group Corp.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:SOUSEIKAI Hakata Clinic Institutional Review Board (Approval number: N-105)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, TY, upon reasonable request, according to the Ethical Guidelines for Medical and Health Research Involving Human Subjects, Japan.